Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) --
-- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement with HealthCare Royalty --
-- Health Canada grants Priority Review status for new drug submission for setmelanotide for treatment of obesity and control of hunger in BBS and biallelic POMC, PCSK1 or LEPR deficiencies --
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that the European Commission (EC) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age and older.
“Patients and families have long endured a significant need for a therapy to address the burdens of hyperphagia and severe obesity often associated with BBS,” said Philip Beales, M.D., University College London, UCL Great Ormond Street Institute of Child Health. “Having new treatment options available can help address the physical and emotional aspects of this devastating disease, offering patients and their families relief and improved quality of life.”
BBS is a rare genetic disease that affects approximately 2,500 people in the European Union (EU) and United Kingdom (UK). People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life. Approximately 1,500 patients have been diagnosed with BBS and are now being cared for at academic settings in the EU and UK.
Under the terms of the Revenue Interest Financing Agreement with HealthCare Royalty Partners announced on June 16, 2022, Rhythm is now eligible to receive an additional investment of $37.5 million following EC marketing authorization for setmelanotide for BBS. Rhythm had received an initial investment amount of $37.5 million from HealthCare Royalty as a result of the approval of setmelanotide by the U.S. Food and Drug Administration (FDA), and the Company remains eligible for an additional investment amount of $25 million, which would be payable upon the achievement of certain agreed sales milestones in 2023.
Priority Review Status Granted for New Drug Submission for Setmelanotide in Canada
Rhythm also announced today that Health Canada has granted Priority Review for Rhythm's New Drug Submission for setmelanotide, indicated in adult and pediatric patients 6 years of age and older with impairments in the MC4R pathway due to genetic diseases, for the treatment of obesity and control of hunger in BBS or biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.
Priority Review shortens Health Canada’s submission review performance target to 180 days, in comparison to 300 days for non-priority review. Priority Review may be granted for drug submissions in Canada for a serious, life-threatening or severely debilitating disease or condition for which there is substantial evidence of clinical effectiveness that the drug provides effective treatment, prevention or diagnosis of a disease or condition for which no drug is presently marketed in Canada or a significant increase in efficacy and/or significant decrease in risk such that the overall benefit/risk profile is improved over existing therapies, preventatives or diagnostic agents for a disease or condition that is not adequately managed by a drug marketed in Canada.
“These two important regulatory milestones underscore the global unmet need to treat the hyperphagia and severe obesity associated with these rare MC4R pathway diseases,” said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. “We are working closely with Health Technology Assessment bodies and payers throughout the EU on a country-by-country basis to achieve market access and reimbursement in order to make IMCIVREE available to eligible patients as rapidly as possible. Taken together with the recent FDA approval for BBS in June, we are making significant advances in our mission of delivering the first precision medicine for MC4R pathway diseases to patients across the world.”
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. Rhythm’s precision medicine, setmelanotide, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). The European Commission (EC) has authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. The UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity and is leveraging the Rhythm Engine and the largest known obesity DNA database -- now with approximately 45,000 sequencing samples -- to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. Rhythm’s headquarters is in Boston, MA.
In the European Union, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) or genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.
In the United States, setmelanotide is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to POMC, PCSK1 or LEPR deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1 or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) or BBS.
Limitations of Use
In the United States and Europe, Setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:
- Obesity due to suspected POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign
- Other types of obesity not related to POMC, PCSK1 or LEPR deficiency, or BBS, including obesity associated with other genetic syndromes and general (polygenic) obesity.
WARNINGS AND PRECAUTIONS
Skin Monitoring: Setmelanotide may lead to generalized increased skin pigmentation and darkening of pre-existing naevi because of its pharmacologic effect. Full body skin examinations should be conducted annually to monitor pre-existing and new skin pigmentary lesions before and during treatment with setmelanotide.
Heart rate and blood pressure monitoring: Heart rate and blood pressure should be monitored as part of standard clinical practice at each medical visit (at least every 6 months) for patients treated with setmelanotide.
Prolonged penile erection: Spontaneous penile erections have been reported in clinical trials with setmelanotide. Patients who have a penile erection lasting longer than 4 hours should be instructed to seek emergency medical attention for potential treatment of priapism.
Depression: In clinical trials, depression has been reported in patients treated with setmelanotide. Patients with depression should be monitored at each medical visit during treatment with setmelanotide. Consideration should be given to discontinuing setmelanotide if patients experience suicidal thoughts or behaviors.
Paediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated. The prescribing physician should monitor growth (height and weight) using age- and sex-appropriate growth curves.
Excipients: This medicinal product contains 10 mg benzyl alcohol in each ml. Benzyl alcohol may cause allergic reactions. Patients who are pregnant or breastfeeding should be advised of the potential risk from the excipient benzyl alcohol, which might accumulate over time and cause metabolic acidosis. This medicinal product should be used with caution in patients with hepatic or renal impairment, because of the potential risk from the excipient benzyl alcohol which might accumulate over time and cause metabolic acidosis.
Sodium: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium-free.”
The most frequent adverse reactions are hyperpigmentation (51%), injection site reaction (39%), nausea (33%), and headache (26%).
USE IN SPECIFIC POPULATIONS
There are no data from the use of setmelanotide in pregnant women. Animal studies do not indicate direct harmful effects with respect to reproductive toxicity. However, administration of setmelanotide to pregnant rabbits resulted in decreased maternal food consumption leading to embryo-foetal effects. As a precautionary measure, setmelanotide should not be started during pregnancy or while attempting to get pregnant as weight loss during pregnancy may result in fetal harm. If a patient who is taking setmelanotide has reached a stable weight and becomes pregnant, consideration should be given to maintaining setmelanotide treatment as there was no proof of teratogenicity in the nonclinical data. If a patient who is taking setmelanotide and still losing weight gets pregnant, setmelanotide should either be discontinued, or the dose reduced while monitoring for the recommended weight gain during pregnancy. The treating physician should carefully monitor weight during pregnancy in a patient taking setmelanotide.
It is unknown whether setmelanotide is excreted in human milk. A nonclinical study showed that setmelanotide is excreted in the milk of nursing rats. No quantifiable setmelanotide concentrations were detected in plasma from nursing pups. A risk to the newborn/infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from setmelanotide therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
No human data on the effect of setmelanotide on fertility are available. Animal studies did not indicate harmful effects with respect to fertility.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337. See Summary of Product Characteristics’APPENDIX V for a list of European national reporting systems to communicate adverse reactions.
Please see the full Prescribing Information for additional Important Safety Information.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress of setmelanotide, the potential benefits of setmelanotide for patients with BBS, and our expectations surrounding potential regulatory submissions, approvals and timing thereof, and our business strategy and plans, including regarding commercialization of setmelanotide in Europe, Canada, the United States and other international regions. Statements using word such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our liquidity and expenses, the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies, clinical trials and commercialization prospects, and general economic conditions, and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and our other filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
Stern Investor Relations, Inc.
Berry & Company Public Relations
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Orkuveita Reykjavíkur | Green Bond Auction December 125.12.2023 18:17:17 CET | Press release
Reykjavík Energy (Orkuveita Reykjavíkur; OR) is holding a bond auction on Tuesday, December 12th, 2023. Bonds in the green bond classes OR020934 GB, OR180255 GB and OR161126 GB will be offered for sale. OR161126 GB bears non-indexed interests with an interest payment arrangement and bears 7.0% interest, payable four times a year until the final maturity on November 16, 2026. Previously, bonds with a nominal value of 720 million have been issued in the class. OR020934 GB bears fixed indexed interests and pays equal payments every six months with a final maturity date of September 2, 2034. Previously, bonds with a nominal value of ISK 21,127 million have been issued in the class. OR0180255 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of February 18, 2055. Previously, bonds with a nominal value of ISK 27,281 million have been issued in the class. Fossar Investment Bank hf. oversees the issuance and sale of the bonds as well as their a
Wereldhave acquires shopping center Polderplein in Hoofddorp, the Netherlands, and enters growth phase of its LifeCentral strategy5.12.2023 17:40:00 CET | Press release
Wereldhave has reached agreement with DELA Vastgoed B.V. (‘DELA’) regarding the acquisition of shopping center Polderplein and its parking garage in Hoofddorp (The Netherlands), with a total gross lettable area of c17,000 m² (excluding parking). The acquisition perfectly fits within Wereldhave’s strategy and acquisition criteria such as location, value creation opportunities and synergies with the recently delivered Full Service Center Vier Meren. Combined, Vier Meren and Polderplein will create one dominant Full Service Center in the best location of the city, with 49,100 m2 lettable area and 105 shops, with Wereldhave as sole owner. The total purchase price amounts to € 74m (€ 82m including transaction costs), reflecting a net initial yield of 7.6%. As the transaction is 70% equity financed, the loan-to-value will improve by c30bps. Matthijs Storm, CEO of Wereldhave commented: “This acquisition marks the start of the growth phase of Wereldhave’s LifeCentral strategy and completes a b
Kvika banki hf.: Result of subordinated bond offering5.12.2023 17:39:25 CET | Press release
Kvika has today concluded an offering of Tier-2 subordinated bonds in a new series, KVIKA 34 1211 T2i. Total demand amounted to ISK 4,820 million. The subordinated bonds were sold at par for an amount of ISK 2,000 million, where total issuance in the series is limited to ISK 4,000 million. The subordinated bonds are index linked and have an annual coupon of 6.25%. The maturity of the bonds is 11 December 2034 and are callable by the issuer at the interest payment date of 11 December 2029 and on every subsequent interest payment date. The subordinated bonds will be issued under Kvika’s EMTN programme and listed on Nasdaq Iceland. For further information please contact Kvika‘s investor relations at firstname.lastname@example.org
Zoom named a Leader in the 2023 Gartner® Magic Quadrant™ for UCaaS, Worldwide5.12.2023 17:31:56 CET | Press release
Zoom Celebrates its Fourth Consecutive Time in the Leaders Quadrant SAN JOSE, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM), today announced that analyst firm Gartner has named Zoom a Leader in the 2023 Gartner® Magic Quadrant™ for Unified Communications as a Service (UCaaS), Worldwide for the fourth time in a row. The UCaaS report evaluated 11 companies in the unified communications space, and Zoom has been recognized as a Leader in this space for its UCaaS offerings. Zoom includes enterprise-grade solutions like Zoom Team Chat, Zoom Phone, Zoom Meetings, Zoom Contact Center, and Zoom AI Companion. “We are excited to be named a Leader in the Gartner Magic Quadrant for UCaaS for the fourth consecutive year which we feel is a result of our ongoing commitment to offer an exceptional UCaaS experience," said Graeme Geddes, Chief Growth Officer at Zoom. “As we continue to innovate and evolve our platform, we remain true to solving real customer probl
Innofactor Plc: Share Repurchase 5.12.20235.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 5.12.2023Innofactor Plc: Share Repurchase 5.12.2023In the Helsinki Stock ExchangeTrade date 5.12.2023Bourse trade BuyShare IFA1VAmount 4,600SharesAverage price/ share 1.1465EURTotal cost 5,273.90EURInnofactor Plc now holds a total of 571 129 sharesincluding the shares repurchased on 5.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 email@example.com Attachment Innofactor_5.12_trades